These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12398964)

  • 1. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
    Hansen MS; Stanton EB; Gawad Y; Packer M; Pitt B; Swedberg K; Rouleau JL;
    Am J Cardiol; 2002 Nov; 90(9):969-73. PubMed ID: 12398964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure.
    Stanton EB; Hansen MS; Sole MJ; Gawad Y; Packer M; Pitt B; Swedberg K; Rouleau JL;
    Can J Cardiol; 2005 Jan; 21(1):39-43. PubMed ID: 15685301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
    Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA
    J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.
    Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K
    Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
    Packer M; Pitt B; Rouleau JL; Swedberg K; DeMets DL; Fisher L
    JACC Heart Fail; 2017 Jun; 5(6):399-407. PubMed ID: 28501522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
    Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
    Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
    Rouleau JL; Pitt B; Dhalla NS; Dhalla KS; Swedberg K; Hansen MS; Stanton E; Lapointe N; Packer M;
    Am Heart J; 2003 May; 145(5):926-32. PubMed ID: 12766756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
    Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
    Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
    Haas GJ; Binkley PF; Carpenter JA; Leier CV
    Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic vasodilator therapy with flosequinan in congestive heart failure.
    Haas GJ; Binkley PE; Leier CV
    Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
    Elborn JS; Stanford CF; Nicholls DP
    Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
    Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
    Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration.
    Binkley PF; Nunziata E; Cody RJ
    Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril.
    Cowley AJ; McEntegart DJ; Hampton JR; Barnett DB; Bexton RS; Boyle R; Hanley SP; Millar-Craig M; Morris GK; Nicholls AJ
    Cardiovasc Drugs Ther; 1994 Dec; 8(6):829-36. PubMed ID: 7742261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
    Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
    BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
    Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated intraoperative expression of ventricular myosin light chain predicts heart failure after valve replacement surgery.
    Feng Q; Zhang GF; Ma L; Ni YM
    Heart Surg Forum; 2011 Dec; 14(6):E340-8. PubMed ID: 22167758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.